Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Terminated 2Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6Expanded_access 1

Sponsor

Cancer Type

Thoracic 6Genitourinary 6Other hematologic neoplasm 5CNS 4Myeloid 3Gynecologic 3Gastrointestinal 3Breast 3Other solid neoplasm 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Lung Neoplasms 1Head and Neck Neoplasms 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × BID protein, human × Thoracic × Clear all
NCT04624204 2026-05-26

MK 7339-013

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
672 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT06128148 2025-07-14

JYP0322

Guangzhou JOYO Pharma Co., Ltd

Phase 1 Recruiting
101 enrolled
CNSThoracic

Brain Neoplasms, Lung Neoplasms

NCT04820023 2025-06-06

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

Bridge Biotherapeutics, Inc.

Phase 1/2 Terminated
45 enrolled 19 charts
Thoracic

NSCLC

NCT06082635 2025-05-18

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Shenzhen TargetRx Co., Ltd.

Phase 3 Active not recruiting
321 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04515979 2024-12-09

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

MedPacto, Inc.

Phase 2 Terminated
11 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡